Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine

Journal of Clinical Gastroenterology

Volumn 37, Issue 1, 2003, Pages 68-71

  Simpson, Nicole D ^b   Simpson, Peter W ^b   Ahmed, Ali M ^b   Nguyen, Mindie H ^b   Garcia, Gabriel ^b   Keeffe, Emmet B ^b   Ahmed, Aijaz ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Chemotherapy; HBV reactivation; Lamivudine

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; DNA SYNTHESIS INHIBITION; DRUG INDUCED DISEASE; EXPERIENCE; FEMALE; HEPATITIS B; HUMAN; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; PROPHYLAXIS; SEROCONVERSION; VIRUS INFECTION; VIRUS REACTIVATION;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; REVERSE TRANSCRIPTASE INHIBITORS; VINCRISTINE; VIRUS ACTIVATION;

EID: 0038274633     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200307000-00017     Document Type: Article

References (35)

1. Wands JR. Subacute and chronic active hepatitis after withdrawal of chemotherapy. Lancet. 1975;2:979.
2. Nagington J. Reactivation of hepatitis B after transplantation operations. Lancet. 1977;1:558-560.
3. Hoofnagle JH, Dusheiko GM, Schafer DF. et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 1982;96:447-449.
4. Thung SN, Gerber MA. Klion F, et al. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med. 1985;145:1313-1314.
5. Pariente EA, Goudeau A. Dubois F, et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogenic bone marrow transplantation. Dig Dis Sci. 1988;33:1185-1191.
6. Grumayer ER, Panzer S. Ferenci P, et al. Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemic chemotherapy. J Hepatol. 1989;8:232-235.
7. Lau JY, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med. 1989;73:911-917.
8. Bird GL, Smith H, Portmann B, et al. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Q J Med. 1989;73:895-902.
9. Liang RH, Lok AS. Lai CL. et al. Hepatitis B infection in patients with lymphomas. Hematol Oncol. 1990;8:261-270.
10. Lok AS. Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182-188.
11. Nakamura Y, Motokura T. Fujita A. et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer. 1996;78:2210-2215.
12. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17:394-398.
13. Alexopoulos CG, Vaslamatzis M. Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer. 1999;81:69-74.
14. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299-307.
15. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657-1661.
16. Lai CL, Ching CK, Tung AK, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebocontrolled trial. Hepatology. 1997;25:241-244.
17. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-68.
18. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263.
19. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000;32:828-834.
20. Buti M, Cotrina M, Jardi R, et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat. 2001;8:270-275.
21. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33:1527-1532.
22. Chang TT, Lai CL, Liaw YF, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV patients treated with lamivudine for four years [Abstract]. Antiviral Therapy 2000;5(suppl1):44.
23. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000;31:207-210.
24. Van Thiel DH, Friedlander L, Kania RJ, et al. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology. 1997;44:808-812.
25. Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol. 1999;94:249-251.
26. Clark FL, Drummond MW, Chambers S, et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkins lymphoma. Ann Oncol. 1998;9:385-387.
27. Yeo W, Steinberg JL, Tam JS, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol. 1999;59:263-269.
28. Yagci M, Sucak GT, Haznedar R. Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia. Am J Hematol. 2000;64:233-234.
29. Saif MW, Little RF, Hamilton JM, et al. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature. Ann Oncol. 2001;12:123-129.
30. Franceschini R, Cataldi A, Tenconi GL, et al. Reactivation of hepatitis B virus infection during cytotoxic chemotherapy. Am J Gastroenterol. 2001;96:606-607.
31. Cainelli F, Longhi MS, Concia E, et al. Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol. 2001;96:1651-1652.
32. Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology. 1988;167:630-633.
33. Al-Taie OH, Mork H, Gassel AM, et al. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann Hematol. 1999;78:247-249.
34. Silvestri F, Ermacora A, Sperotto A, et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol. 2000;108:394-396.
35. Endo T, Sakai T, Fujimoto K, et al. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2001;27:433-436.